InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.73
(
0.18%
)
Bitcoin
60,856.50
(
2.73%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Kag

Send PM Follow Ignore
Followers 1
Posts 788
Boards Moderated 0
Alias Born 02/01/2006

Kag

Re: bocxman post# 3868

Thursday, 05/25/2006 5:57:00 PM

Thursday, May 25, 2006 5:57:00 PM

Post# of 30387
Confused? Hardly.

No wonder Abbott is taking so long to determine its "feasibility review." They have to develop a RECAF blood test to run on their automated analyzers and also have to deal with the varying amounts of RECAF in normal people. It is not difficult to understand why the first milestone is a "feasibility review." The varying amounts of RECAF in the blood of normal people has the potential to be a huge problem for early detection tests. BioCurex has been working on this problem since March 2002 (over 4 years ago) and essentially said in the May 16, 2006 press release that they do not know if it is solvable or not. kag
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up